Anna-Dorothea Gorki
Chief Scientific Officer YGION Biomedical
Anna‑Dorothea Gorki, PhD is an immunologist and experienced biotech executive, currently serving as Chief Scientific Officer at YGION Biomedical, where she leads the development of precision medicine strategies for cancer immunotherapies. Previously, she was CSO at a start-up, developing antiviral therapies for respiratory infections leading the preclinical team up to clinical phase II. Dr. Gorki completed her PhD in immunology at the Medical University of Vienna and CeMM Research Center for Molecular Medicine, authoring high-impact publications in top-tier journals such as “Cell”. Her work has earned multiple distinctions, including the Austrian Science Ministry’s Award of Excellence and the State Prize of Austria.
Seminars
- Pre-screening in glioblastoma – Identifying patients with sufficient tumour material and actionable neoantigen profiles for a personalised, targeted peptide-based immunotherapy
- Mechanistic basis and planned immune readouts – A targeted peptide-based approach designed to prime neoantigen-specific T-cell responses, with immune monitoring assays being established to capture activation, breadth, and durability once treatment begins
- Pathways to scalability – Identifying key drivers such as prediction accuracy, manufacturing performance, and workflow coordination that will enable future scaling of personalised peptide-based programmes
